Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma

Askar Obulkasim, Bauke Ylstra, Hendrik F. van Essen, Christian Benner, Sally Stenning, Ruth Langley, William Allum, David Cunningham, Imran Inam, Lindsay C. Hewitt, Nicolas P. West, Gerrit A. Meijer, Mark A. van de Wiel, Heike I. Grabsch

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)44084-44095
Number of pages12
JournalOncotarget
Volume7
Issue number28
DOIs
Publication statusPublished - 12 Jul 2016

Keywords

  • esophageal adenocarcinoma
  • array CGH
  • prognosis
  • chemotherapy

Cite this

Obulkasim, A., Ylstra, B., van Essen, H. F., Benner, C., Stenning, S., Langley, R., Allum, W., Cunningham, D., Inam, I., Hewitt, L. C., West, N. P., Meijer, G. A., van de Wiel, M. A., & Grabsch, H. I. (2016). Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 7(28), 44084-44095. https://doi.org/10.18632/oncotarget.9857